CA2834243C - Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody - Google Patents

Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody Download PDF

Info

Publication number
CA2834243C
CA2834243C CA2834243A CA2834243A CA2834243C CA 2834243 C CA2834243 C CA 2834243C CA 2834243 A CA2834243 A CA 2834243A CA 2834243 A CA2834243 A CA 2834243A CA 2834243 C CA2834243 C CA 2834243C
Authority
CA
Canada
Prior art keywords
antibody
seq
ser
cell
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2834243A
Other languages
English (en)
French (fr)
Other versions
CA2834243A1 (en
Inventor
Tomohide YAMAZAKI
Jing Zhao
Koji Ishida
Yasue SHIBATA
Minkwon Cho
Mayuki ENDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Publication of CA2834243A1 publication Critical patent/CA2834243A1/en
Application granted granted Critical
Publication of CA2834243C publication Critical patent/CA2834243C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CA2834243A 2011-04-28 2012-04-27 Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody Active CA2834243C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011101752 2011-04-28
JP2011-101752 2011-04-28
PCT/JP2012/061795 WO2012148003A1 (en) 2011-04-28 2012-04-27 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY

Publications (2)

Publication Number Publication Date
CA2834243A1 CA2834243A1 (en) 2012-11-01
CA2834243C true CA2834243C (en) 2019-08-27

Family

ID=46147004

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2834243A Active CA2834243C (en) 2011-04-28 2012-04-27 Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody

Country Status (16)

Country Link
US (2) US9803026B2 (OSRAM)
EP (2) EP3232202B1 (OSRAM)
JP (2) JP6001557B2 (OSRAM)
KR (1) KR101873614B1 (OSRAM)
CN (1) CN103703372B (OSRAM)
AU (2) AU2012248158C1 (OSRAM)
CA (1) CA2834243C (OSRAM)
ES (2) ES2788183T3 (OSRAM)
HU (2) HUE054211T2 (OSRAM)
IL (1) IL229127A (OSRAM)
MX (1) MX352599B (OSRAM)
PL (2) PL3232202T3 (OSRAM)
PT (2) PT3232202T (OSRAM)
RU (2) RU2013152816A (OSRAM)
SG (3) SG10202108240VA (OSRAM)
WO (1) WO2012148003A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP3232202B1 (en) * 2011-04-28 2020-02-19 SBI Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase antibody
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
KR20150036603A (ko) * 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 결합제 및 그의 용도
WO2014018554A1 (en) 2012-07-23 2014-01-30 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
US11160873B2 (en) * 2014-02-04 2021-11-02 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
WO2015117199A1 (en) * 2014-02-04 2015-08-13 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
KR20170094787A (ko) * 2014-12-18 2017-08-21 에프. 호프만-라 로슈 아게 Cdc 유발 항체를 측정하기 위한 검정 및 방법
MX2019011252A (es) * 2017-03-23 2020-01-23 Univ Pennsylvania Anticuerpos anti-c5a y usos de los mismos.
US20200132673A1 (en) * 2017-03-24 2020-04-30 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
US11242398B2 (en) 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
EP3826612A4 (en) * 2018-07-25 2022-09-14 Accurus Biosciences, Inc. NOVEL CLDN-18.2-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF USE
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members
WO2021067633A2 (en) * 2019-10-04 2021-04-08 Albert Einstein College Of Medicine Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
US20250082734A1 (en) 2021-07-30 2025-03-13 The Regents Of The University Of California Ptprs in autoimmunity
CN114426582B (zh) * 2022-01-07 2022-11-25 陕西脉元生物科技有限公司 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用
CN116041526B (zh) * 2022-11-14 2023-09-29 华中农业大学 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
WO2024186740A2 (en) * 2023-03-03 2024-09-12 Case Western Reserve University Cell adhesion molecule targeted immunotherapies
CN118994384B (zh) * 2024-08-09 2025-09-26 陕西脉元生物科技有限公司 抗Ri的人源化单克隆抗体及其应用和基于其的检测方法
CN119874900B (zh) * 2025-03-06 2025-10-17 吉林大学 一种单克隆抗体及其在制备治疗肿瘤药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173217A1 (en) * 1993-10-01 1995-04-13 Joseph Schlessinger Novel receptor-type phosphotyrosine phosphatase-sigma
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
EP1607404A4 (en) * 2003-03-14 2008-01-23 Taisho Pharmaceutical Co Ltd MONOCLONAL ANTIBODY AND HYBRIDOM THAT PRODUCES THIS
EP1732650A4 (en) 2004-03-27 2008-06-11 Univ Arizona COMPOSITION AND METHOD FOR CANCER TREATMENT
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2007041317A2 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
WO2009003274A1 (en) * 2007-06-29 2009-01-08 The Hospital For Sick Children Susceptibility gene for inflammatory bowel disease
ES2796111T3 (es) * 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
WO2011022462A2 (en) * 2009-08-18 2011-02-24 President And Fellows Of Harvard College Neural regeneration
EP2531859A4 (en) * 2010-02-02 2013-07-31 Jolla Inst Allergy Immunolog Compositions and methods of modulating receptor protein tyrosine phosphatases
EP3232202B1 (en) * 2011-04-28 2020-02-19 SBI Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase antibody

Also Published As

Publication number Publication date
KR20140033024A (ko) 2014-03-17
ES2638088T3 (es) 2017-10-18
RU2013152816A (ru) 2015-06-10
AU2012248158C1 (en) 2017-02-02
BR112013027631A2 (pt) 2022-01-04
EP2702412B1 (en) 2017-07-26
US20140127223A1 (en) 2014-05-08
AU2016262677B2 (en) 2018-08-30
IL229127A0 (en) 2013-12-31
RU2017118262A (ru) 2018-11-02
KR101873614B1 (ko) 2018-07-02
SG10201503257WA (en) 2015-06-29
RU2017118262A3 (OSRAM) 2018-11-02
PT3232202T (pt) 2020-05-22
US10730955B2 (en) 2020-08-04
AU2012248158B2 (en) 2016-09-08
HUE054211T2 (hu) 2021-08-30
PT2702412T (pt) 2017-11-02
MX352599B (es) 2017-11-30
SG10202108240VA (en) 2021-09-29
AU2012248158A1 (en) 2014-01-30
IL229127A (en) 2017-11-30
MX2013012393A (es) 2014-04-30
CN103703372B (zh) 2018-01-26
JP6412072B2 (ja) 2018-10-24
EP3232202A1 (en) 2017-10-18
AU2016262677A1 (en) 2016-12-08
WO2012148003A1 (en) 2012-11-01
US9803026B2 (en) 2017-10-31
RU2715642C2 (ru) 2020-03-02
US20180155446A1 (en) 2018-06-07
PL3232202T3 (pl) 2020-10-05
JP2014524733A (ja) 2014-09-25
JP6001557B2 (ja) 2016-10-05
EP3232202B1 (en) 2020-02-19
PL2702412T3 (pl) 2018-01-31
JP2017048183A (ja) 2017-03-09
ES2788183T3 (es) 2020-10-20
EP2702412A1 (en) 2014-03-05
CA2834243A1 (en) 2012-11-01
SG194614A1 (en) 2013-12-30
CN103703372A (zh) 2014-04-02
HUE034752T2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
CA2834243C (en) Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody
US12312410B2 (en) Anti-CD39 antibodies
CN111788225B (zh) 抗cd38抗体及与抗cd3和抗cd28抗体的组合
CN106715471B (zh) 抗cd127的抗体
TWI654201B (zh) Ｐｄ－１抗體、其抗原結合片段及其醫藥用途
KR101931591B1 (ko) 항－ｉｌ－２３ 항체
KR20190059958A (ko) 항-lag-3 항체 및 조성물
KR20170064550A (ko) 인간화 항-ox40 항체 및 이의 용도
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
CN101952426A (zh) 抗bst2抗体
TW202210520A (zh) 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用
CN114685660A (zh) 抗cldn18.2抗体及其制备方法和应用
JP2023513200A (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
CN115151570A (zh) 抗人cd19抗体
CN113135994A (zh) 一种激活型抗ox40抗体、生产方法及应用
KR102901666B1 (ko) 항-인간 cd19 항체
RU2812910C2 (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28
HK40076013A (en) Anti-cldn18.2 antibody, and preparation method and use thereof
TW202448504A (zh) Btn3a活化抗體及免疫檢查點抑制劑之組合
HK1153502B (en) Anti-bst2 antibody

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170427